Abstract
Antiaggregant treatment is suitable for all at risk patients with atherothrombosis and its cardiovascular complications. Antiaggregant treatment decreases severe vascular events in at risk patients, myocardial infarctions, non-fatal strokes, transient ischemic attack, unstable angina, obstructive peripheral vascular disease.
It decreases a risk of embolism caused by atrial fibrillation and a risk of vascular occlusion in other patients at high risk. Antiaggregant treatment should be administered long-term.
The basis antiaggregant drug is acetylsalicylic acid (ASA) which is commonly used in doses of 75-150 mg daily. ASA is an effective antiaggregant drug with clearly demonstrated beneficial effect on atherothrombotic complications in cardiovascular disease.
Other substances and drugs with antiaggregant effect inducing their modes of action and indications are reviewed.